Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,408 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
Regulatory Filings Classification · 88% confidence The document is a Sanofi press release (“Communiqué de presse”) announcing FDA priority review of a new drug application for venglustat, describing clinical trial results and regulatory designations. It contains no financial data, no summary financial results, no management changes, no dividend or share issue, and does not itself present a financial or audit report. It is a general regulatory/market announcement that does not fit any specialized category, so it should be classified as a general Regulatory Filing (RNS).
2026-05-28 French
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Regulatory Filings Classification · 88% confidence The document is a corporate press release announcing that the FDA has accepted Sanofi’s new drug application for priority review of venglustat. It contains clinical study details, regulatory designations, and forward-looking statements, but it is not an earnings release, financial report, management discussion, or formal SEC filing of results. It is a general corporate announcement/regulatory update. None of the specific categories (earnings release, IR, 10-K, M&A, etc.) fit. Therefore, by fallback, this is classified as a general regulatory/business announcement under Regulatory Filings (RNS).
2026-05-28 English
6-K
Regulatory Filings
2026-05-27 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2026
Regulatory Filings Classification · 82% confidence The document is a regulatory announcement disclosing Sanofi’s total number of shares and voting rights under French commercial code and AMF regulations. It does not present meeting results, vote outcomes, or constitute a financial report; rather it is a compliance filing. No specific category matches exactly, so it falls under the fallback “Regulatory Filings” (RNS).
2026-05-19 French
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Regulatory Filings Classification · 82% confidence The document is a statutory announcement under French Commercial Code and AMF rules providing the total number of shares and voting rights as of a certain date. It is neither a full financial report nor a vote result, nor a threshold‐crossing shareholding notice. It is a regulatory disclosure of share and voting‐rights structure, thus best classified as a general regulatory filing (RNS).
2026-05-19 English
Communiqué de presse : ATS : Les données de phase 2 démontrent la supériorité de l'efdoralprin alfa par rapport au traitement de substitution standard pour atteindre des taux de fAAT plus élevés dans
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi dated May 18, 2026, presenting clinical trial phase 2 data for a drug candidate (efdoralprin alfa) for alpha-1 antitrypsin deficiency (DAAT). It discusses study results, safety data, and regulatory designations such as Fast Track and orphan drug status. The document is a detailed announcement of clinical trial results and regulatory status, not a financial report, earnings release, or management discussion. It is not a regulatory filing or certification. It is not an investor presentation or annual/interim report. It is a press release focused on clinical data and regulatory updates. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit other specific categories.
2026-05-18 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.